{"id":16698,"date":"2026-04-14T11:45:48","date_gmt":"2026-04-14T14:45:48","guid":{"rendered":"https:\/\/www.biolabeco.com.br\/?post_type=imprensa&#038;p=16698"},"modified":"2026-04-14T11:45:49","modified_gmt":"2026-04-14T14:45:49","slug":"ans-evaluates-including-high-cost-medication-to-prevent-new-heart-attacks-and-strokes","status":"publish","type":"imprensa","link":"https:\/\/www.biolabeco.com.br\/en\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/","title":{"rendered":"ANS evaluates including high-cost medication to prevent new heart attacks and strokes"},"content":{"rendered":"<p>Public consultation open until April 28 discusses mandatory coverage of therapy that reduces \u201cbad\u201d cholesterol in high-risk patients<\/p>\n\n\n\n<p>A&nbsp;<strong>National Supplementary Health Agency<\/strong>&nbsp;has opened a public consultation that could expand access to a treatment considered innovative in the prevention of cardiovascular diseases. The proposal analyzes the inclusion of Anti-PCSK9 therapy in the List of Health Procedures and Events, which would oblige health plans to offer the drug to eligible patients.<\/p>\n\n\n\n<p>The measure is aimed at adults who have already suffered serious events, such as&nbsp;<a href=\"https:\/\/diariodopara.com.br\/tag\/infarto\/\"><strong>heart attack<\/strong><\/a>&nbsp;or stroke, and are at high risk of recurrence. Scientific data indicates that around 1 in 5 patients may face a new cardiovascular episode in the first year after the initial event, which reinforces the need for more effective prevention strategies.<\/p>\n\n\n\n<p>The drug, developed by Amgen and marketed in Brazil by Biolab Farmac\u00eautica, works to reduce LDL, known as \u201cbad cholesterol\u201d. This type of fat is directly linked to the formation of plaques in the arteries, a process called\u00a0<strong>atherosclerosis<\/strong>, which can trigger heart attacks and strokes.<\/p>\n\n\n\n<p>Indicated mainly for patients who are unable to control the\u00a0<strong>cholesterol<\/strong>\u00a0with conventional drugs, the therapy is considered high-tech and has the potential to reduce hospitalizations and serious complications.<\/p>\n\n\n\n<p>A\u00a0<strong>public consultation<\/strong>\u00a0The process is open until April 28 and allows health professionals, patients and society in general to submit contributions through the official ANS portal. The process is part of a social participation mechanism that helps inform decisions on the incorporation of new technologies into the supplementary health system.<\/p>\n\n\n\n<p>1 - Go to<a href=\"https:\/\/www.gov.br\/ans\/pt-br\">\u00a0portal of\u00a0<strong>ANS<\/strong>\u00a07<\/a>. Please note: you need to be registered on the portal<a href=\"http:\/\/gov.br\/\">\u00a0gov.br<\/a><br>2 - Go to the side menu and click on: \u201cACCESS TO INFORMATION\u201d &gt; \u201cSOCIAL PARTICIPATION\u201d &gt; \u201cPUBLIC CONSULTATIONS\u201d.<br>3 - Find the public consultation you want: Search for the public consultation you are interested in in the Current Public Consultations section - this is identified by the public consultation number (INCLUDE PUBLIC CONSULTATION NUMBER) and the title - and click on \u201cPARTICIPATE\u201d.<br>4 - Scroll to the bottom of the page and click on \u201cCONTRIBUTE\u201c.<br>5 - Fill in the form: You identify yourself as a health professional,\u00a0<a href=\"https:\/\/diariodopara.com.br\/tag\/infarto\/\">patient<\/a>\u00a0or family, and can attach studies or simply their position on the proposal.<br>6 - To finish, click on \u201cSend contribution\u201d.<br>The form provided by\u00a0<strong>ANS<\/strong>\u00a0is simple to fill in - you identify yourself as a health professional, patient or family member, and you can attach studies, share clinical data or simply your position on the proposal. Finally, click on \u201csend contributions\u201d.<br><br>Check out the full article: <a href=\"https:\/\/diariodopara.com.br\/dr-responde\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/\">ANS evaluates including high-cost medication to prevent new heart attacks and strokes<\/a> <\/p>\n\n\n\n<p><a href=\"https:\/\/diariodopara.com.br\/autor\/luiz-augusto\/\"><\/a><\/p>","protected":false},"featured_media":16701,"template":"","categories":[1577],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.4 (Yoast SEO v24.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ANS avalia incluir medicamento de alto custo para prevenir novos infartos e AVCs - Biolab &amp; Co<\/title>\n<meta name=\"description\" content=\"A\u00a0ANS\u00a0abriu uma consulta p\u00fablica que pode ampliar o acesso a um tratamento considerado inovador na preven\u00e7\u00e3o de doen\u00e7as cardiovasculares.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biolabeco.com.br\/en\/press\/ans-evaluates-including-high-cost-medication-to-prevent-new-heart-attacks-and-strokes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANS avalia incluir medicamento de alto custo para prevenir novos infartos e AVCs\" \/>\n<meta property=\"og:description\" content=\"A\u00a0ANS\u00a0abriu uma consulta p\u00fablica que pode ampliar o acesso a um tratamento considerado inovador na preven\u00e7\u00e3o de doen\u00e7as cardiovasculares.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biolabeco.com.br\/en\/press\/ans-evaluates-including-high-cost-medication-to-prevent-new-heart-attacks-and-strokes\/\" \/>\n<meta property=\"og:site_name\" content=\"Biolab &amp; Co\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T14:45:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"987\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/\",\"url\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/\",\"name\":\"ANS avalia incluir medicamento de alto custo para prevenir novos infartos e AVCs - Biolab &amp; Co\",\"isPartOf\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg\",\"datePublished\":\"2026-04-14T14:45:48+00:00\",\"dateModified\":\"2026-04-14T14:45:49+00:00\",\"description\":\"A\u00a0ANS\u00a0abriu uma consulta p\u00fablica que pode ampliar o acesso a um tratamento considerado inovador na preven\u00e7\u00e3o de doen\u00e7as cardiovasculares.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#primaryimage\",\"url\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg\",\"contentUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg\",\"width\":1800,\"height\":987,\"caption\":\"O medicamento, desenvolvido pela Amgen e comercializado no Brasil pela Biolab Farmac\u00eautica, atua na redu\u00e7\u00e3o do LDL, conhecido como \u201ccolesterol ruim\u201d\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biolabeco.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANS avalia incluir medicamento de alto custo para prevenir novos infartos e AVCs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\",\"url\":\"https:\/\/www.biolabeco.com.br\/\",\"name\":\"Biolab\",\"description\":\"Na Biolab &amp; Co, ci\u00eancia e cuidado caminham juntos. Saiba como promovemos sa\u00fade com responsabilidade socioambiental e tecnologia.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biolabeco.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ANS evaluates including high-cost drug to prevent new heart attacks and strokes - Biolab &amp; Co","description":"The ANS has opened a public consultation that could expand access to a treatment considered innovative in the prevention of cardiovascular diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biolabeco.com.br\/en\/press\/ans-evaluates-including-high-cost-medication-to-prevent-new-heart-attacks-and-strokes\/","og_locale":"en_US","og_type":"article","og_title":"ANS avalia incluir medicamento de alto custo para prevenir novos infartos e AVCs","og_description":"A\u00a0ANS\u00a0abriu uma consulta p\u00fablica que pode ampliar o acesso a um tratamento considerado inovador na preven\u00e7\u00e3o de doen\u00e7as cardiovasculares.","og_url":"https:\/\/www.biolabeco.com.br\/en\/press\/ans-evaluates-including-high-cost-medication-to-prevent-new-heart-attacks-and-strokes\/","og_site_name":"Biolab &amp; Co","article_modified_time":"2026-04-14T14:45:49+00:00","og_image":[{"width":1800,"height":987,"url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/","url":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/","name":"ANS evaluates including high-cost drug to prevent new heart attacks and strokes - Biolab &amp; Co","isPartOf":{"@id":"https:\/\/www.biolabeco.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#primaryimage"},"image":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg","datePublished":"2026-04-14T14:45:48+00:00","dateModified":"2026-04-14T14:45:49+00:00","description":"The ANS has opened a public consultation that could expand access to a treatment considered innovative in the prevention of cardiovascular diseases.","breadcrumb":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#primaryimage","url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg","contentUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/04\/Biolab-consulta-publica-ANS-foto.jpg","width":1800,"height":987,"caption":"O medicamento, desenvolvido pela Amgen e comercializado no Brasil pela Biolab Farmac\u00eautica, atua na redu\u00e7\u00e3o do LDL, conhecido como \u201ccolesterol ruim\u201d"},{"@type":"BreadcrumbList","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/ans-avalia-incluir-medicamento-de-alto-custo-para-prevenir-novos-infartos-e-avcs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biolabeco.com.br\/"},{"@type":"ListItem","position":2,"name":"ANS avalia incluir medicamento de alto custo para prevenir novos infartos e AVCs"}]},{"@type":"WebSite","@id":"https:\/\/www.biolabeco.com.br\/#website","url":"https:\/\/www.biolabeco.com.br\/","name":"Biolab","description":"At Biolab &amp; Co, science and care go hand in hand. Find out how we promote health with social and environmental responsibility and technology.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biolabeco.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/16698"}],"collection":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa"}],"about":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/types\/imprensa"}],"version-history":[{"count":1,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/16698\/revisions"}],"predecessor-version":[{"id":16699,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/16698\/revisions\/16699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/media\/16701"}],"wp:attachment":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/media?parent=16698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/categories?post=16698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}